138 related articles for article (PubMed ID: 33532606)
1. A study to assess the unmet medical needs associated with the use of basal insulin in patients with type 2 diabetes.
Frechtel G; Forti L; Faingold C; Perez Mangui F; Orio S; Issa C; Guaita MS; Vivas N; De Luca JA
Endocrinol Diabetes Metab; 2021 Jan; 4(1):e00164. PubMed ID: 33532606
[TBL] [Abstract][Full Text] [Related]
2. The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real-world setting.
Meneghini LF; Mauricio D; Orsi E; Lalic NM; Cali AMG; Westerbacka J; Stella P; Candelas Dea C; Pilorget V; Perfetti R; Khunti K;
Diabetes Obes Metab; 2019 Jun; 21(6):1429-1436. PubMed ID: 30768845
[TBL] [Abstract][Full Text] [Related]
3. Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: A longitudinal study of a US administrative claims database.
Tong L; Pan C; Wang H; Bertolini M; Lew E; Meneghini LF
Diabetes Obes Metab; 2018 Apr; 20(4):831-839. PubMed ID: 29119712
[TBL] [Abstract][Full Text] [Related]
4. Self-reported non-severe hypoglycaemic events in Europe.
Östenson CG; Geelhoed-Duijvestijn P; Lahtela J; Weitgasser R; Markert Jensen M; Pedersen-Bjergaard U
Diabet Med; 2014 Jan; 31(1):92-101. PubMed ID: 23796113
[TBL] [Abstract][Full Text] [Related]
5. Real-world patient-reported rates of non-severe hypoglycaemic events in Germany.
Kulzer B; Seitz L; Kern W
Exp Clin Endocrinol Diabetes; 2014 Mar; 122(3):167-72. PubMed ID: 24643694
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis.
Huthmacher JA; Meier JJ; Nauck MA
Diabetes Care; 2020 Sep; 43(9):2303-2312. PubMed ID: 32910778
[TBL] [Abstract][Full Text] [Related]
7. Switching from Neutral Protamine Hagedorn Insulin to Insulin Glargine 300 U/mL Improves Glycaemic Control and Reduces Hypoglycaemia Risk: Results of a Multicentre, Prospective, Observational Study.
Wolnik B; Wiza D; Szczepanik T; Syta A; Klupa T
J Diabetes Res; 2020; 2020():8751348. PubMed ID: 32337298
[TBL] [Abstract][Full Text] [Related]
8. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
Jacober SJ; Scism-Bacon JL; Zagar AJ
Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
[TBL] [Abstract][Full Text] [Related]
9. Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real-world results from the DELIVER Naïve cohort study.
Bailey TS; Zhou FL; Gupta RA; Preblick R; Gupta VE; Berhanu P; Blonde L
Diabetes Obes Metab; 2019 Jul; 21(7):1596-1605. PubMed ID: 30843339
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal-L-C randomized trial.
Yang W; Min K; Zhou Z; Li L; Xu X; Zhu D; Venkateshwar Rao A; Murthy LS; Zhang N; Li I; Niemoeller E; Shang S
Diabetes Obes Metab; 2018 Feb; 20(2):335-343. PubMed ID: 28742225
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study.
Sullivan SD; Bailey TS; Roussel R; Zhou FL; Bosnyak Z; Preblick R; Westerbacka J; Gupta RA; Blonde L
Diabetes Obes Metab; 2018 Sep; 20(9):2148-2158. PubMed ID: 29938887
[TBL] [Abstract][Full Text] [Related]
12. Comparable efficacy with similarly low risk of hypoglycaemia in patient- vs physician-managed basal insulin initiation and titration in insulin-naïve type 2 diabetic subjects: The Italian Titration Approach Study.
Bonadonna RC; Giaccari A; Buzzetti R; Perseghin G; Cucinotta D; Avogaro A; Aimaretti G; Larosa M; Fanelli CG; Bolli GB
Diabetes Metab Res Rev; 2020 Sep; 36(6):e3304. PubMed ID: 32118347
[TBL] [Abstract][Full Text] [Related]
13. Real-world outcomes of addition of insulin glargine 300 U/mL (Gla-300) to glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in people with type 2 diabetes: The DELIVER-G study.
Bailey TS; Gill J; Jones S M; Shenoy L; Nicholls C; Westerbacka J
Diabetes Obes Metab; 2022 Aug; 24(8):1617-1622. PubMed ID: 35491520
[TBL] [Abstract][Full Text] [Related]
14. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2).
Terauchi Y; Koyama M; Cheng X; Takahashi Y; Riddle MC; Bolli GB; Hirose T
Diabetes Obes Metab; 2016 Apr; 18(4):366-74. PubMed ID: 26662838
[TBL] [Abstract][Full Text] [Related]
15. Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c.
Gallwitz B; Dagogo-Jack S; Thieu V; Garcia-Perez LE; Pavo I; Yu M; Robertson KE; Zhang N; Giorgino F
Diabetes Obes Metab; 2018 Feb; 20(2):409-418. PubMed ID: 28817231
[TBL] [Abstract][Full Text] [Related]
16. GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: A systematic review and meta-analysis.
Castellana M; Cignarelli A; Brescia F; Laviola L; Giorgino F
Diabetes Metab Res Rev; 2019 Jan; 35(1):e3082. PubMed ID: 30270567
[TBL] [Abstract][Full Text] [Related]
17. Frequency and predictors of confirmed hypoglycaemia in type 1 and insulin-treated type 2 diabetes mellitus patients in a real-life setting: results from the DIALOG study.
Cariou B; Fontaine P; Eschwege E; Lièvre M; Gouet D; Huet D; Madani S; Lavigne S; Charbonnel B
Diabetes Metab; 2015 Apr; 41(2):116-25. PubMed ID: 25465273
[TBL] [Abstract][Full Text] [Related]
18. Self-reported Hypoglycaemic Events in 2 430 Patients with Insulin-treated Diabetes in the German Sub-population of the HAT Study.
Kern W; Holstein A; Moenninghoff C; Kienhöfer J; Riedl M; Kulzer B
Exp Clin Endocrinol Diabetes; 2017 Oct; 125(9):592-597. PubMed ID: 28750429
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
[TBL] [Abstract][Full Text] [Related]
20. Glycaemic outcomes of an Individualized treatMent aPproach for oldER vulnerable patIents: A randomized, controlled stUdy in type 2 diabetes Mellitus (IMPERIUM).
Heller SR; Pratley RE; Sinclair A; Festa A; Kiljański J; Brusko CS; Duan R; Heine RJ
Diabetes Obes Metab; 2018 Jan; 20(1):148-156. PubMed ID: 28671753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
